Latest News and Press Releases

STOUGHTON, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will present two posters featuring real-world data from its portfolio of...

– Paris Hilton shares her personal ADHD journey and encourages others to see ADHD in a new light – –Together, Paris and Collegium are reframing common stereotypes and highlighting experiences that...

STOUGHTON, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in the following investor conferences: ...

– Generated Quarterly Net Revenues of $205.4 Million, Up 13% Year-over-Year, and Record Full-Year Net Revenues of $780.6 Million, Up 24% Year-over-Year – – Generated Record Quarterly and Full-Year...

BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Boston Legacy FC today announced a multi-year partnership with Collegium Pharmaceutical, an emerging biopharmaceutical leader in the Boston area, naming the...

STOUGHTON, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report fourth quarter and full-year 2025 financial results before the...

STOUGHTON, Mass., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will have four poster presentations highlighting real-world data from its ADHD...

– Product Revenues, Net Expected in the Range of $805 Million to $825 Million – – Jornay PM® Net Revenue Expected in the Range of $190 Million to $200 Million – – Adjusted EBITDA* Expected in the...

STOUGHTON, Mass., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), today announced the closing of its inaugural syndicated credit facility. The new aggregate $980...

STOUGHTON, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in the following investor conferences: ...